Unlocking the Science of Cannabis
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
Here is a small sampling of Diabetic Neuropathy studies by title:
Ready to become a subscriber? Go to our PRICING page.
Diabetic-related neuropathies refer to a group of nerve disorders caused by long-term high blood sugar levels in people with diabetes. There are several types of diabetic neuropathies, including large and small fiber neuropathies, peripheral and proximal neuropathies, autonomic neuropathies, and focal neuropathy.
Peripheral neuropathy is the most common type of diabetic neuropathy, affecting the nerves in the feet, legs, hands, and arms. It can cause symptoms such as numbness, tingling, burning, or stabbing pain in the affected areas, as well as weakness and loss of coordination.
Autonomic neuropathy affects the nerves that control involuntary functions such as digestion, heart rate, and blood pressure. As a result, it can cause symptoms such as nausea, vomiting, diarrhea, constipation, bladder problems, and sexual dysfunction.
Proximal neuropathy affects the nerves in the hips, thighs, and buttocks, causing muscle weakness and pain.
Focal neuropathy affects a specific nerve or group of nerves, causing sudden weakness or pain in the affected area.
Diabetic neuropathies can be challenging to treat and significantly impact an individual's quality of life. Treatment may include blood sugar control, medications to manage symptoms, physical therapy, and lifestyle changes such as regular exercise and a healthy diet.
Prevention is critical in managing diabetic neuropathies, and maintaining reasonable blood sugar control can help prevent or delay the onset of nerve damage. Regular check-ups and monitoring of blood sugar levels are also crucial for the early detection and management of diabetic neuropathies.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting CANN-DIR, published by Penn State College of Medicine.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.